Amgen sues FDA to get paediatric exclusivity for Sensipar

30-05-2017

Amgen sues FDA to get paediatric exclusivity for Sensipar

vladimirsorokin / iStockphoto.com

Amgen has filed a complaint against the US Food and Drug Administration (FDA) for not accepting its study reports and denying six months of paediatric exclusivity for its drug Sensipar (cinacalcet).


Amgen, FDA, paediatric exclusivity, Sensipar, patent,

LSIPR